NSE: ONESOURCE · 28 October 2026
- Onesource Specialty Pharma has risen 12.79% over 2 trading sessions; today's move is -0.87%.
- Onesource Specialty Pharma announced its consolidated financial results for the quarter ended September 30, 2026, reporting revenue of ₹5,162 million, which represents a 37% increase year-on-year and 15% growth sequentially. EBITDA reached ₹1,633 million, up 53% year-on-year and 32% quarter-on-quarter, with EBITDA margins expanding to 31.6% driven by operating leverage and higher volumes. Adjusted PAT stood at ₹937 million with an adjusted EPS of ₹8.2.
- Trading volume was 6.21 times the 20-day average daily volume.
Onesource Specialty Pharma share price: 12.79% rise over 2 trading sessions
Onesource Specialty Pharma Ltd. (ONESOURCE) traded down 0.87% at ₹1576.0 on October 28, 2026, moving within an intraday range of ₹1563.7 and ₹1642.9 after opening higher at ₹1620.0.
The broader market exhibited mild weakness, with the Nifty index losing 0.22%. In contrast, the Nifty Pharma sector benchmark advanced 1.04%, reflecting relative strength across pharmaceutical equities. Despite the sectoral gains, ONESOURCE retreated slightly from its opening levels following strong upward momentum over the preceding trading days, which included a 13.78% return in the prior session and a 19.17% return over the past two sessions.
Company disclosures from October 27, 2026, outlined the financial performance for the quarter ended September 30, 2026, reporting consolidated revenue of ₹5,162 million—up 37% year-on-year and 15% sequentially—alongside an EBITDA of ₹1,633 million, representing a 53% year-on-year increase. While these strong earnings and operational updates regarding new drug-device combination capacity expansion provide fundamental context for the recent multi-day rally, today's marginal price correction appears consistent with normal profit-taking following substantial prior gains.
36.98 lakh shares traded by 28 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 5.95 lakh shares (6.21 times). The five-day average daily volume was 17.13 lakh shares. Separately, the NSE report for 27 October 2026 showed 12.61 lakh shares delivered, representing 16.16% of that day’s traded volume. The same report recorded 353,406 trades.
The stock experienced a minor intraday pullback of 0.87% after surging significantly over the prior two trading sessions (gaining 13.78% in the previous trading day and 19.17 over two sessions). Heavy volume participation and positive Q2 earnings announcements provided underlying operational context, but today's minor retracement aligns with typical profit-taking following sharp short-term gains.
Latest Company Developments
Onesource Specialty Pharma announced its consolidated financial results for the quarter ended September 30, 2026, reporting revenue of ₹5,162 million, which represents a 37% increase year-on-year and 15% growth sequentially. EBITDA reached ₹1,633 million, up 53% year-on-year and 32% quarter-on-quarter, with EBITDA margins expanding to 31.6% driven by operating leverage and higher volumes. Adjusted PAT stood at ₹937 million with an adjusted EPS of ₹8.2.
Demonstrates robust operational scaling and margin expansion supported by new manufacturing capacities and product launches across business segments.
The board approved the change in designation of Dr. Claudio Albrecht from Independent Director to Non-Executive Non-Independent Director, subject to shareholder approval. Dr. Albrecht brings extensive industry experience from leadership roles across major international pharmaceutical and generics companies.
Shifts board composition to align strategic advisory oversight with ongoing international business expansion.
a press release dated October 27, 2026, titled "OneSource Announces Strong Q2FY27 ResultsRevenue up 37% YoY and EBITDA up 53% YoY".
Onesource Specialty Pharma Limited has submitted to the Exchange, the unaudited financial results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026.
OneSource Specialty Pharma shares jump 14% after Q2 results; recover 50% from recent lows Livemint
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 13.76% on 30 September 2026. This compares with 12.98% on 30 June 2026, a change of +0.78 percentage points.
The filing reported 25 MF/UTI holders.
What to Watch Next
- Execution and commercial ramp-up of the newly commercialized second cartridge line and facility capacities
- Progress on additional product launches across North America, MENA, LatAm, and Canada
- Delivery percentage and volume trends relative to the 20-day average volume
- Board and shareholder approvals regarding management and director designation updates
Other Dated Coverage
More Onesource Specialty Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Onesource Specialty Pharma company news?
Onesource Specialty Pharma announced its consolidated financial results for the quarter ended September 30, 2026, reporting revenue of ₹5,162 million, which represents a 37% increase year-on-year and 15% growth sequentially. EBITDA reached ₹1,633 million, up 53% year-on-year and 32% quarter-on-quarter, with EBITDA margins expanding to 31.6% driven by operating leverage and higher volumes. Adjusted PAT stood at ₹937 million with an adjusted EPS of ₹8.2.
How strong was Onesource Specialty Pharma’s trading volume?
36.98 lakh shares traded, 6.21 times the 20-day average daily volume. The price and volume data are dated 28 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.